Homepage | TALZENNA® (talazoparib) | Safety Info TALZENNA ® treats g BRCA -mutated, HER2- breast cancer that is locally advanced or metastatic TALZENNA is a proven alternative to chemotherapy in a convenient once-daily oral dose
label - Food and Drug Administration TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human
TALZENNA™ - Pfizer This product information is intended only for residents of the United States Pfizer Oncology Together™ provides financial assistance resources to help patients access their prescribed Oncology medicines
Talzenna, INN-talazoparib - European Medicines Agency Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated